论文部分内容阅读
组胺H_2受体拮抗剂的广泛应用是消化性溃疡治疗史上的一大进步,大部分溃疡患者经过严格的内科治疗(包括一般治疗、制酸剂及标准剂量的H_2受体拮抗剂)后于4～8周内治愈。但仍有少数患者(约5％～10％)久治不愈或短期内又复发,一般称这类溃疡为“难治性溃疡”(Refracory Ulcer)。目前难治性溃疡的定义是:经用标准剂量的H_2受体拮抗剂治疗后,经胃镜确定,十二指肠溃疡在8周末不愈合,胃溃疡在12周末不愈合。胃溃疡出现难愈情况较十二指肠溃疡更为多见,而十二指肠溃疡较胃溃疡更容易复发。本文仅就难治性溃疡的研究现状作以简述。
Histamine H 2 receptor antagonist is widely used in the history of treatment of peptic ulcer a major step forward, most of the ulcer patients undergo a rigorous medical treatment (including general treatment, antacids and standard dose of H 2 receptor antagonist) after 4 to 8 weeks to cure. However, a small number of patients (about 5% to 10%) still have a long-term recurrence or relapse within a short period of time. Such ulcers are commonly referred to as Refracory Ulcer. The current definition of refractory ulcer is: After treatment with a standard dose of H 2 receptor antagonist, determined by endoscopy, duodenal ulcers at 8 weeks did not heal, gastric ulcer at 12 weeks did not heal. Gastric ulcer recurrence is more common than duodenal ulcer, and duodenal ulcer recurrence is more likely than gastric ulcer. This article only on the research status of refractory ulcer to make a brief description.